Galmed Pharmaceuticals (GLMD) Net Income (2013 - 2026)
Galmed Pharmaceuticals (GLMD) posted quarterly Net Income of -$1.9 million for Q1 2026, down 73.01% year-over-year from -$7.1 million in Q1 2025, and down 0.95% quarter-over-quarter from -$1.9 million in Q3 2025.
Galmed Pharmaceuticals (GLMD) Net Income (2013 - 2026) Analysis & Trends
Galmed Pharmaceuticals' Net Income history runs 14 years deep, the most recent figure standing at -$1.9 million for Q1 2026.
- In Q1 2026, Net Income fell 73.01% year-over-year to -$1.9 million; the TTM figure through Mar 2026 stood at -$6.3 million (up 5.83% YoY), while the FY2025 annual figure was -$316000.0, up 21.0% from the prior year.
- Net Income for Q1 2026 stood at -$1.9 million, down from -$1.9 million in the prior quarter.
- The five-year high for Net Income was $17.0 million in Q4 2022, with the low at -$25.1 million in Q3 2022.
- The 5-year median for Net Income is -$1.5 million (2023), against an average of -$359714.3.
- The sharpest annual moves came in 2022 and 2023: Net Income surged 214.09% in 2022, then tumbled 714.09% in 2023.
- Galmed Pharmaceuticals' Net Income stood at $17.0 million in 2022, then tumbled by 91.34% to $1.5 million in 2023, then slumped by 229.94% to -$1.9 million in 2024, then climbed by 1.15% to -$1.9 million in 2025, then dropped by 0.95% to -$1.9 million in 2026.
- Business Quant data shows GLMD's Net Income at -$1.9 million in Q1 2026, -$1.9 million in Q3 2025, and -$2.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 81.49 Mn |
| 10 | Galmed Pharmaceuticals | 2.34 Mn | -9.54 Mn | - | 1.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.91 Mn |
| Sep 30, 2025 | -1.89 Mn |
| Jun 30, 2025 | -2.50 Mn |
| Mar 31, 2025 | -1.10 Mn |
| Sep 30, 2024 | -1.91 Mn |
| Jun 30, 2024 | -3.67 Mn |
| Mar 31, 2024 | 1.28 Mn |
| Sep 30, 2023 | 1.47 Mn |
| Jun 30, 2023 | 5.25 Mn |
| Mar 31, 2023 | -1.83 Mn |
| Dec 31, 2022 | 17.00 Mn |
| Sep 30, 2022 | -25.10 Mn |
| Jun 30, 2022 | 9.58 Mn |
| Mar 31, 2022 | 298,000.00 |
| Dec 31, 2021 | -57.48 Mn |
| Sep 30, 2021 | 42.32 Mn |
| Jun 30, 2021 | -8.40 Mn |
| Mar 31, 2021 | -8.91 Mn |
| Dec 31, 2020 | 10.28 Mn |
| Sep 30, 2020 | 30.08 Mn |